Skip to main content
Top

2006 | OriginalPaper | Hoofdstuk

Is toediening van allopurinol bij jicht ten gevolge van diuretica bij hartfalen zinvol?

Auteurs : Dr. T.L.Th.A. Jansen, Dr. E.N. van Roon

Gepubliceerd in: Vademecum permanente nascholing huisartsen

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Het korte antwoord op deze vraag luidt: ‘ja, want iedere verlaging van serumuraatconcentratie geeft een verlaging van risico op jichtaanvallen’. Uiteraard verdient deze korte beantwoording nog wel wat bespiegeling. Bij diureticagebruikers dringen de volgende vragen zich op: Kan het staken van een urinezuurverhogend diureticum alleen al een afdoende zinnige actie zijn? Of dient urinezuurverlaging perse door middel van een xanthine-oxidaseremmer (XOR) en/of uricosuricum te worden bereikt? Welk lijden volgt er eigenlijk uit door-diuretica-verhoogde urinezuurconcentraties? En, is er bewijs voor de werking van XOR bij jicht secundair aan urinezuurspiegelverhogende diuretica? In het onderstaande willen we de “evidences” belichten.
Literatuur
go back to reference Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham study. J Clin Epidemiol 1988; 41: 237-42. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham study. J Clin Epidemiol 1988; 41: 237-42.
go back to reference Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894-900. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894-900.
go back to reference Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA study. Hypertension 2000; 36: 1072-78. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA study. Hypertension 2000; 36: 1072-78.
go back to reference Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-56. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-56.
go back to reference Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-97. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-97.
go back to reference Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998; 29: 635-39. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998; 29: 635-39.
go back to reference Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart study. Ann Intern Med 1999; 131: 7-13. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart study. Ann Intern Med 1999; 131: 7-13.
go back to reference Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. JAMA 2000; 283: 2404-10. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. JAMA 2000; 283: 2404-10.
go back to reference Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96). J Rheumatol 2001; 28: 1640-46. Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96). J Rheumatol 2001; 28: 1640-46.
go back to reference Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39: 1227-33. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39: 1227-33.
go back to reference Janssen HJEM, Lisdonk EH van de, Janssen M, Hoogen HJM van den, Verbeek ALM. Gout, not induced by diuretics? A case-control study from primary care. ARD 2006; 65: 1080-3. Janssen HJEM, Lisdonk EH van de, Janssen M, Hoogen HJM van den, Verbeek ALM. Gout, not induced by diuretics? A case-control study from primary care. ARD 2006; 65: 1080-3.
go back to reference Reinders MK, Roon EN van, Jansen TL, Delsing J, Griep EN, Hoekstra M, Laar MAFJ van de, Brouwers JRBJ. Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. ARD 2008 Epub 18250122: 2009;68:51-6. doi 10.1136/ard.2007.083071. Reinders MK, Roon EN van, Jansen TL, Delsing J, Griep EN, Hoekstra M, Laar MAFJ van de, Brouwers JRBJ. Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. ARD 2008 Epub 18250122: 2009;68:51-6. doi 10.1136/ard.2007.083071.
go back to reference Reinders MK, Haagsma C, Jansen TLThA, Roon EN van, Delsing J, Laar MAFJ van de, Brouwers JRBJ. A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. ARD 2009: 68:892-7. doi: 20.1136/ard.2008.091462 Reinders MK, Haagsma C, Jansen TLThA, Roon EN van, Delsing J, Laar MAFJ van de, Brouwers JRBJ. A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. ARD 2009: 68:892-7. doi: 20.1136/ard.2008.091462
Metagegevens
Titel
Is toediening van allopurinol bij jicht ten gevolge van diuretica bij hartfalen zinvol?
Auteurs
Dr. T.L.Th.A. Jansen
Dr. E.N. van Roon
Copyright
2006
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-8808-0_1616